Stem cells may fix COPD lungs – early study launched
NCT ID NCT06755008
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether induced pluripotent stem cells (iPS cells) can repair damaged lung tissue from people with COPD. Researchers will take small lung samples from 50 participants (COPD patients, smokers without COPD, and non-smokers) during a routine bronchoscopy. In the lab, they will grow the tissue and see if adding iPS cells helps it heal faster. This is a basic science study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- induced pluripotent stem cells (iPS cells)
- What this could lead to
- If successful, this could point toward a cell-based therapy to repair lung damage in COPD patients.
- What could go wrong
- This is a very early, small lab-based study (50 people) looking at cells in a dish, not a treatment in humans. It may not lead to any real-world therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
General Inclusion Criteria * Male and female participants aged 18 years or older. * Participants with a bronchoscopy indication determined by a pulmonologist (e.g., follow-up exploration, nodule investigation, hemoptysis, cough, sputum production, recurrent bronchitis, or differential diagnosis). Group 1 Inclusion Criteria: COPD * Current or former smokers (≥10 pack-years). * Diagnosed with COPD: FEV1/FVC \< 0.7 (confirmed by spirometry available in the medical file within the past year). Group 2 Inclusion Criteria: Smokers without COPD (n=10) * Current or former smokers (≥10 pack-years). * No obstructive ventilatory disorder identified by clinical examination and/or (FEV1/FVC \> 0.7 and FEV1 \> 70% of predicted values) confirmed by spirometry within the past year. Group 3 Inclusion Criteria: Non-smoker controls (n=10) * Never-smokers or former smokers who quit more than 10 years ago (\<10 pack-years). * No obstructive ventilatory disorder identified by clinical examination and/or (FEV1/FVC \> 0.7 and FEV1 \> 70% of predicted values) confirmed by spirometry within the past year. Exclusion Criteria: * Participant with extensive neoplastic disease. * Participant with another progressive pulmonary condition (e.g., asthma, tuberculosis, interstitial lung disease, active or recent pulmonary infection). * Participant consuming illicit drugs or alcohol. * Individual deprived of liberty (by judicial or administrative decision, or under involuntary hospitalization). * Individual currently enrolled in another research study with an ongoing exclusion period. * Participant with recent psychiatric disorders (e.g., involuntary hospitalization, mental health conditions preventing informed consent, or requiring immediate medical intervention). * Adult under legal protection (e.g., guardianship, curatorship, or judicial protection). * Participant unable to provide informed consent. * Participant not fluent in French and without a trusted person to assist with comprehension. * Participant not affiliated with or covered by a social security system. * Pregnant or breastfeeding women. * Participant refusing to provide consent after being informed. * Participant unable or incapable of expressing consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary disease, chronic obstructive are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital of Montpellier, Arnaud de Villeneuve Hospital
RECRUITINGMontpellier, Hérault, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.